Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ASCO 2019 | Treating high-risk myeloma in the elderly

Ashley Rosko • 1 Jun 2019
ASCO 2019
Multiple Myeloma

Many challenges present themselves in the treatment of myeloma in the geriatric population. Ashley Elizabeth Rosko, MD, from Ohio State University, Columbus, OH, discusses these challenges and how to improve treatment outcomes in these patients at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

More from Ashley Rosko

Frailty-adapted treatment in newly diagnosed multiple myeloma 2:43
Frailty-adapted treatment in newly diagnosed multiple myeloma
Ashley Rosko • 18 Sep 2025
The importance of myeloma-specific frailty indices in trial design 1:23
The importance of myeloma-specific frailty indices in trial design
Ashley Rosko • 26 Sep 2024
Blood-based biomarker strategy for assessing physiological age when treating myeloma 0:58
Blood-based biomarker strategy for assessing physiological age when treating myeloma
Ashley Rosko • 26 Sep 2024
The importance of incorporating frailty assessment tools in clinical practice for multiple myeloma 0:52
The importance of incorporating frailty assessment tools in clinical practice for multiple myeloma
Ashley Rosko • 26 Sep 2024

Related Videos

The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial 10:22
The FDA approval of daratumumab for high-risk smoldering myeloma based on the AQUILA trial
Peter Voorhees • 19 Nov 2025
Promising approaches being explored in high-risk myeloma & trials to look out for 2:11
Promising approaches being explored in high-risk myeloma & trials to look out for
Sham Mailankody • 24 Oct 2025
The value of extensive profiling in single-arm trials for high-risk myeloma 2:39
The value of extensive profiling in single-arm trials for high-risk myeloma
Martin Kaiser • 24 Oct 2025
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy? 2:35
How is the definition of high-risk myeloma evolving in the era of CAR T-cell therapy?
Sham Mailankody • 24 Oct 2025
The content of VJHemOnc is intended for healthcare professionals